Vystar Corp.

Vystar Corp. (OTC: VYST) is a materials science company that has developed Vytex Natural Rubber Latex (NRL) — a purified natural rubber latex material with significantly reduced allergenic protein content compared to conventional natural rubber latex — for use in medical gloves, condoms, catheters, and other medical and consumer products where natural rubber allergy is a significant clinical and commercial concern. According to its website at vystar.com, Vytex NRL is produced through a proprietary purification process that removes the majority of the Hevea brasiliensis tree proteins responsible for natural rubber latex allergies — proteins that cause IgE-mediated allergic reactions ranging from localized skin rashes through severe anaphylaxis in sensitized individuals. The reduction of allergenic proteins in Vytex NRL enables the production of natural rubber latex products with the performance advantages of natural rubber — including superior elasticity, barrier properties, and tactile sensitivity — while significantly reducing the allergy risk associated with conventional natural rubber latex.

Vystar's Vytex NRL technology, described at vystar.com, purifies natural rubber latex through a centrifugation and washing process that progressively removes the soluble proteins and other extractable materials responsible for latex sensitization, producing a consistently low-protein NRL that meets the FDA's lowest-level protein detection thresholds for medical grade latex products. The material's superior allergenic protein removal compared to conventional deproteinized natural rubber latex provides latex product manufacturers with the ability to produce products that are more suitable for healthcare workers, patients, and consumers who have demonstrated latex sensitivity or who are at elevated risk of latex sensitization through repeated exposure to conventional natural rubber latex products. Vystar licenses its Vytex NRL technology and purification processes to natural rubber latex manufacturers and compounders who incorporate the purification technology into their latex processing operations.

Vystar Corp. pursues the commercial development of Vytex NRL through technology licensing arrangements with latex manufacturers, materials compounders, and medical device and consumer product companies seeking to incorporate low-protein natural rubber latex into their product lines. According to vystar.com, the company's licensing strategy targets both medical product manufacturers — where latex allergy is a significant clinical liability and the demand for low-protein latex products is well-established — and consumer product manufacturers in categories such as household gloves, balloons, and other consumer products where natural rubber latex allergy affects a meaningful proportion of potential users. Vystar's combination of purified natural rubber latex technology, allergenic protein reduction innovation, medical and consumer product application focus, technology licensing business model, and OTC-listed public company structure reflects its positioning as a specialty materials technology licensor serving the latex product manufacturing industry.